 In a financial notice posted earlier today, Astellas Pharma Inc OTCMKTS: ALPMY said it was taking an impairment loss of 58.8 billion 540 million because of last years FDA clinical hold on Audentes AT132, gene therapy X-linked myotubular myopathy XLMTM, a rare muscle-wasting disorder that is usually evident at birth. Last year, Audentes told patient groups that an XLMTM patient had died after receiving AT132. 